Synapse

← Meletios Α. Dimopoulos

Papers by Meletios Α. Dimopoulos

Page 1 · newest first

  1. Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and DexamethasoneJournal of Clinical Oncology · 2026
  2. Outcomes of Patients With AL Amyloidosis and End‐Stage Renal Disease After Initiation of TherapyAmerican Journal of Hematology · 2026
  3. Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myelomaBlood Cancer Journal · 2026
  4. Survival of patients newly diagnosed with mayo stage iiia/iiib cardiac light chain amyloidosis on a bortezomib- or daratumumab-based therapy by isotype: results from a single site retrospective studyEuropean Heart Journal Supplements · 2026
  5. Independent prognostic value of semaphorin-4D, interleukin-1β and complement activation in newly diagnosed multiple myeloma patientsHaematologica · 2026
  6. Myeloma Elderly Prognostic Score ( MEPS ): A Proposed Prognostic Score Integrating Age, Renal Function, Performance Status, and Ultra‐High‐Risk CytogeneticsAmerican Journal of Hematology · 2026
  7. Progression of Disease Within 24 Months (POD24) is an Independent Prognostic Factor for Survival in Waldenström MacroglobulinemiaClinical Lymphoma Myeloma & Leukemia · 2026
  8. International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary PlasmacytomasJournal of Clinical Oncology · 2026
  9. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialThe Lancet · 2026
  10. Signals in Peripheral Blood: Tracking Redox Status and DNA Damage Response During the Progression of Multiple MyelomaInternational Journal of Molecular Sciences · 2026
  11. Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centreBritish Journal of Haematology · 2026
  12. Distinct immune and genomic signatures predict resistance to ibrutinib therapy in Waldenström macroglobulinemia2026
  13. The Hippo Pathway in Metaplastic Breast Carcinoma: Prognostic Significance and Therapeutic ImplicationsCurrent Issues in Molecular Biology · 2025
  14. Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbsBlood · 2025
  15. Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA StudyJournal of Clinical Oncology · 2025
  16. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine · 2025
  17. Safety and efficacy of linvoseltamab (LINVO) combined with anti-CD38 monoclonal antibodies (mAbs) daratumumab (DARA) or isatuximab (ISA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the multicohort, Phase 1b LINKER-MM2 trialBlood · 2025
  18. Incidence and risk factors for infections in the real-world setting in newly diagnosed myeloma patients treated with modern induction regimensBlood · 2025
  19. Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survivalBlood · 2025
  20. Results of the promise study from ~30,000 individuals screened for monoclonal gammopathiesBlood · 2025
  21. Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study groupBlood · 2025
  22. Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patientsBlood · 2025
  23. Von willebrand factor levels show independent prognostic significance in patients with AL amyloidosis treated with daratumumab-based therapiesBlood · 2025
  24. Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progressionBlood · 2025
  25. Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3Blood · 2025
  26. Epigenetics in Ovarian Cancer: A Review of Current Knowledge and Future PerspectivesBiomedicines · 2025
  27. Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysisBlood · 2025
  28. Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma NetworkHemaSphere · 2025
  29. Cold pressor test and paradoxical blood pressure reduction in light chain amyloidosisAmyloid · 2025
  30. Bone disease burden does not impact overall survival in newly diagnosed patients with multiple myeloma − a single center, retrospective imaging analysis on 119 patientsJournal of bone oncology · 2025
  31. Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast NephropathyAmerican Journal of Hematology · 2025
  32. GLP‐1 receptor agonists in patients with MGUS: A real‐world propensity‐matched studyEuropean Journal of Clinical Investigation · 2025
  33. Circulating tumor cells by Next Generation Flow Cytometry as a new prognostic biomarker for patients with asymptomatic monoclonal gammopathiesBlood Cancer Journal · 2025
  34. SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T CellClinical Lymphoma Myeloma & Leukemia · 2025
  35. Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX studyLeukemia & lymphoma/Leukemia and lymphoma · 2025
  36. Current experiences with teclistamab in patients with multiple myeloma and renal impairmentExpert Review of Hematology · 2025
  37. Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemiaBlood · 2025
  38. National strategies for screening neural tube defects in Saudi Arabia: activating prevention and early interventionFrontiers in Public Health · 2025
  39. A rare splenic and pancreatic inflammatory myofibroblastic tumour with left‑sided portal hypertension and gastric varices: A case reportExperimental and Therapeutic Medicine · 2025
  40. The predictive value of inotropic reserve in risk stratification of cancer patients with antineoplastic therapy-induced cardiotoxicityEuropean Heart Journal Supplements · 2025
  41. Pomalidomide, cyclophosphamide and dexamethasone for relapsed/refractory multiple myeloma; a single-center experienceClinical Lymphoma Myeloma & Leukemia · 2025
  42. Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma NetworkHemaSphere · 2025
  43. Serum Proteomics of Ribociclib‐Mediated Cardiovascular Toxicity: An Exploratory Case–Control StudyPROTEOMICS - CLINICAL APPLICATIONS · 2025
  44. Dialysis independence for a young patient with refractory multiple myeloma treated with teclistamab: A case reportOncology Letters · 2025
  45. Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 TrialsBlood Advances · 2025
  46. Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular EventsAmerican Journal of Hematology · 2025
  47. Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single InstitutionAmerican Journal of Hematology · 2025
  48. Isatuximab for the treatment of multiple myeloma: current clinical advances and future directionsExpert Opinion on Investigational Drugs · 2025
  49. Lymphadenopathy is an independent prognostic factor for patients with Waldenström macroglobulinaemiaBritish Journal of Haematology · 2025
  50. Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström’s MacroglobulinemiaClinical Lymphoma Myeloma & Leukemia · 2025